China Resources Boya Bio-pharmaceutical Group (300294) investor relations material

Executive summary

• Revenue for Q3 2025 reached ¥466.15 million, up 33.43% year-over-year; YTD revenue was ¥1.47 billion, up 18.38% year-over-year, mainly due to the consolidation of Green Cross.

• Net profit attributable to shareholders for Q3 was ¥117.62 million, up 21.59% year-over-year; YTD net profit was ¥342.96 million, down 16.90% year-over-year, impacted by inventory write-downs and asset amortization from the Green Cross acquisition.

• Net profit excluding non-recurring items for Q3 was ¥44.35 million, down 42.59% year-over-year; YTD was ¥209.90 million, down 37.55% year-over-year, mainly due to lower net profit and the disposal of Boya Xinhe.

Financial highlights

• Operating cash flow for Q3 was ¥26.11 million, down 90.05% year-over-year, due to increased consolidation scope and slower cash collection.

• Basic and diluted EPS for Q3 were ¥0.23, up 21.05% year-over-year; YTD EPS was ¥0.68, down 17.07% year-over-year.

• Total assets at Q3-end were ¥8.73 billion, up 3.88% from year-end 2024; shareholders’ equity was ¥7.67 billion, up 2.45%.

• Gross margin and operating margin were pressured by higher costs and increased expenses from the Green Cross integration.

Outlook and guidance

• Management expects continued revenue growth from expanded business scope but notes ongoing margin pressure and cash flow challenges due to integration costs and market conditions.